- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
OneOncology, Foundation Medicine Create Partnership to Deliver Targeted Care
A community oncology practice network and a cancer genomics firm announced an initiative to expand opportunities for real-time precision medicine as well as research participation.
OneOncology, a network of nearly 170 community oncology care sites, and cancer genomic profiling firm Foundation Medicine said Monday they are partnering to give patients and physicians access to genomic profiling tools as well as expanded research opportunities.
“Our goal is to offer comprehensive genomic profiling to all patients who might potentially benefit from it," said Lee Schwartzberg, M.D., chief medical officer at OneOncology, in an interview with The American Journal of Managed Care®, adding, "knowing their genomic landscape will be very helpful to inform treatment decisions in multiple lines of therapy."
The initiative willl allow for one analytic platform where clinicians could search and identify patients with genomic alterations that make them eligible to participate in certain clinical trials, he said. The database will allow the community oncology practices to get patients into targeted therapy trials, particularly in cases where there are "tissue agnostic" alterations and mutations that exist across different cancers.
In addition, Schwartzberg said, OneOncology will help Foundation Medicine to create new assays for community oncology practices.
“Through this partnership, we have the opportunity to design studies from the patients’ perspective and create rapid learning environments to advance patient care,” Brian Alexander, MD, MPH, chief medical officer at Foundation Medicine, in a statement. “This is particularly important for diseases for which there is no standard of care where we need to learn and test hypotheses in new ways.”
In other words, Schwartzberg noted, not every mutation is actionable now, but may be in the future, and that is where the database comes in, he said. As new drugs get developed, it is necessary to know where they can have an impact, citing, for example, HER2-positive alterations, which are expressed in different cancers.
"There's an increasing number of these," he said.
Health Equity and Access Weekly Roundup: December 2, 2023
December 2nd 2023The Center on Health Equity and Access highlights the most recent updates in the realm of health equity, including news, research findings, and initiatives focused on mitigating health care disparities and enhancing overall access to quality care.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Consumers should not eat precut cantaloupe if they do not know the source, as the number of illnesses and recalls tied to a deadly salmonella outbreak grows; the White House and the Department of Education urged schools to take proactive steps to prevent youth drug use; a study published this week found a high prevalence of arrhythmia in patients with long COVID.
Read More
